BioCentury | Apr 4, 2016
Company News

Boehringer Ingelheim, Centrexion Therapeutics deal

...Centrexion acquired from Boehringer pain compounds CNTX-6970 , CNTX-6016 and CNTX-0290 . CNTX-6970, a selective cytokine...
...CCR2 ; CD192 ) antagonist, is in Phase I testing to treat inflammatory pain. CNTX-6016...
...in preclinical testing to treat mixed nociceptive and neuropathic pain. Centrexion expects clinical testing of CNTX-6016...
BioCentury | Mar 31, 2016
Company News

Centrexion acquires Boehringer pain compounds

...the molecule has shown "very attractive properties" in models of inflammatory pain. Centrexion also obtained CNTX-6016...
Items per page:
1 - 2 of 2